2015: The beginning of the end of the war against malaria

Main Article Content

Richard Tjan


In May 2015 the 62th World Health Assembly formulated a global malaria strategy for 2016-2030 aiming to “reduce the global disease burden by 40% by 2020, and by at least 90% by 2030. It also aims to eliminate malaria in at least 35 new countries by 2030”.(1) As a reminder, it was 60 years ago that the Eighth World Health Assembly decided in 1955 to shift from malaria control to malaria eradication, with the aim to make many areas of free of malaria “within 10 to 15 years”.(2) This has yet to be accomplished in many malaria endemic countries such as Indonesia, where the earliest program was the malaria eradication program of 1959, evolving into the malaria control program, the roll-back malaria program, and finally in 2012 into the malaria elimination program.(3) In view of the ever-present insecticideresistance

Article Details

How to Cite
Tjan, R. (2015). 2015: The beginning of the end of the war against malaria. Universa Medicina, 34(2), 77–78. https://doi.org/10.18051/UnivMed.2015.v34.77-78
Review Article
Author Biography

Richard Tjan, Universitas Trisakti

Fakultas Kedokteran Universitas Trisakti


World Health Organization. World Health Assembly agrees global malaria strategy and programme budget 2016-17. Geneva: World Health Organization;2015.

Mayo CW, Brady FJ. The eighth world health assembly. Public Health Rep 1955;70:1057-60.

Kusriastuti R, Surya A. New treatment policy of malaria as a part of malaria control program in Indonesia. Acta Med Indones 2012;44:265-9.

The PATH Malaria Vaccine Initiative (MVI). Fact sheet: The RTS,S malaria vaccine candidate (MosquirixTM);2015.

The RTS,S Clinical Trials Partnership. A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N Engl J Med 2012;367:2284-95. DOI: 10.1056/NEJMoa1208394.

RTS,S Clinical Trials Partnership. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet 2015;386:31-45.

Glaxo Smith Kline Biologicals and PATH Malaria Vaccine Initiative. RTS,S/AS01 candidate malaria vaccine-summary for the SAGE meeting;2009.

Stoute JA, Kester KE, Krzych U, et al. Longterm efficacy and immune responses following immunization with the RTS,S malaria vaccine. J Infect Dis 1998;178:1139-44.